Ensign Peak Advisors
AZN icon

Ensign Peak Advisors’s AstraZeneca AZN Stock Holding History

Ensign Peak Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4M Buy
+53,761
New +$10.4M 0.02% 401
2024
Q1 		– Sell
-359,341
Closed -$48.4M – 1726
2023
Q4 		$48.4M Sell
359,341
-932,996
-72% -$121M 0.1% 190
2023
Q3 		$175M Buy
1,292,337
+45,409
+4% +$6.2M 0.37% 62
2023
Q2 		$178M Buy
1,246,928
+72,969
+6% +$10.7M 0.36% 62
2023
Q1 		$163M Buy
1,173,959
+109,480
+10% +$14.7M 0.35% 73
2022
Q4 		$144M Buy
1,064,479
+10,227
+1% +$1.28M 0.33% 79
2022
Q3 		$116M Sell
1,054,252
-277,994
-21% -$35.3M 0.29% 82
2022
Q2 		$176M Buy
1,332,246
+133,077
+11% +$17.5M 0.42% 60
2022
Q1 		$159M Buy
1,199,169
+770,757
+180% +$92.4M 0.32% 71
2021
Q4 		$49.9M Buy
428,412
+343,348
+404% +$40.4M 0.1% 186
2021
Q3 		$10.2M Buy
85,064
+2,709
+3% +$315K 0.02% 427
2021
Q2 		$9.87M Buy
82,355
+8
+0% +$878 0.02% 430
2021
Q1 		$8.19M Sell
82,347
-5,140
-6% -$517K 0.02% 474
2020
Q4 		$8.75M Buy
+87,487
New +$9.27M 0.02% 448
2020
Q3 		– Sell
-92,533
Closed -$9.79M – 1745
2020
Q2 		$9.79M Buy
92,533
+86,243
+1,371% +$8.91M 0.03% 431
2020
Q1 		$562K Sell
6,290
-22,134
-78% -$2.08M ﹤0.01% 1362
2019
Q4 		$2.83M Buy
+28,424
New +$2.68M 0.01% 883

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Ensign Peak Advisors's AZN Position: Q1 2026 in Review

Ensign Peak Advisors opened a new position in AstraZeneca (AZN) in Q1 2026: 53,761 shares worth $10.4M. The stake represents 0.02% of the portfolio and ranks #401 among its holdings. This is a return to the name: Ensign Peak Advisors previously reported a position in AZN as recently as Q4 2023.

Ensign Peak Advisors first reported a position in AZN in Q4 2019 and has held it in 17 quarters since. The position peaked at $178M in Q2 2023. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Ensign Peak Advisors held 53,761 shares of AstraZeneca worth $10.4M as of Q1 2026.
  • AstraZeneca was a new Ensign Peak Advisors position in Q1 2026.
  • AstraZeneca made up 0.02% of Ensign Peak Advisors's portfolio in Q1 2026, its #401 holding.
  • Ensign Peak Advisors first reported a position in AstraZeneca in Q4 2019 and has held it in 17 quarters since.
  • Ensign Peak Advisors's AstraZeneca position peaked at $178M in Q2 2023.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.